UNSPSC 51282509: Cefazaflur

This classification denotes a cephalosporin antibiotic with the molecular formula C13H13F3N6O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 97I0692RNT chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-7-((((trifluoromethyl)thio)acetyl)amino)-, (6r-trans)- but generally known as cefazaflur, which bears US NIH Compound Identifier 40239.

UNSPSC 51282509 Cefazaflur (Commodity) represents pharmaceutical products procured by state and local health agencies, though recent state and local solicitations show limited activity directly under this code. The opportunities in the recent pipeline involve antibiotics and emergency medical supplies — Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets through a state pharmaceutical warehouse contract, and Naloxone plus drug deactivation systems through a county health procurement — rather than cefazaflur specifically. State and local buyers under this code tier include state departments of public health and county health departments; the Illinois Department of Public Health and Seminole County, Florida appear as recent issuing bodies.

Recent activity clusters in the South and Midwest. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 (IFB 26482DPHPREPDB53392, closed) for antibiotic tablets with 12-month initial term and two optional renewal years. Seminole County, Florida released an IFB in June 2026 (IFB60459723LAS, response deadline July 26, 2023) for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building. The county's procurement included FEMA funding eligibility and required E-Verify compliance and standard insurance coverage. The code shows sparse recent state and local procurement activity; the opportunities posted do not center on cefazaflur but on related emergency pharmaceuticals and harm-reduction products.